• Khilyatul Mufida RSUD dr. R. Koesma Tuban
Keywords: COVID-19 Vaccine, CoronaVac, Disorientation, Memory Impairment


Vaccination is one of the important strategies to resolve the Coronavirus Disease 2019 (COVID-19) pandemic. Several side effects of vaccination have been reported and the safety of COVID-19 vaccination should be a concern. A 35-year-old man came to the Emergency Room (ER) because he didn’t remember his family members. He received the second dose of CoronaVac vaccine two days before the presentation to ER. The patient fully recovered after received treatment within 24 hours. Disorientation and memory impairment after COVID-19 vaccination in this case may be caused by hypercoagulation due to vaccination or due to coincidence. Thus, it may induce a cerebrovascular disease. Disorientation and memory impairment following CoronaVac vaccination is a rare case. It should be as an alert. Currently, the benefits of vaccine are greater than the side effects. Thus, vaccination against COVID-19 should be encouraged.


1. Ibn-Mohammed T, Mustapha KB, Godsell J, et al. A critical analysis of the impacts of COVID-19 on the global economy and ecosystems and opportunities for circular economy strategies. Resour Conserv Recycl. 2021; 164:105169.
2. Lenzen M, Li M, Malik A, Pomponi F, et al. Global socio-economic losses and environmental gains from the Coronavirus pandemic. PLoS ONE. 2020. 15(7): e0235654.
3. Masyeni, S, Johar, E, Budhitresna, AAG.et al. Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. COVID 2022, 2, 485–491.
4. Fadlyana, E, Rusmil, K, Tarigan, R, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia. Vaccine 2021, 39, 6520–8.
5. Tanriover, MD, Do?ganay, HL, Akova, M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021, 398, 213–222.
6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403e416.
7. Vitiello A, Ferrara, F, Troiano V, et al. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 2021. 29 (5), 1357–1360.
8. Sriwastava S, Sharma K, Khalid SH, et al. COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case. Series. Brain Sci. 2022, 12, 407. 1-14
9. Lu L, Xiong W, Mu J, et al. The potential neurological effect of the COVID-19 vaccines: A review. Acta Neurol. Scand. 2021, 144, 3–12.
10. Prasad A, Hurlburt, G, Podury, S, et al. A Novel Case of Bifacial Diplegia Variant of Guillain-Barré; Syndrome Following Janssen COVID-19 Vaccination. Neurol. Int. 2021, 13, 404–409.
11. Chaurasia B, Chavda V, Lu B, et al. Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. Brain Behav Immun Health. 2022; 22:100463.
12. Hameed S, Khan AF, Khan S, et al. First Report of Cerebral Venous Thrombosis Following Inactivated-Virus Covid Vaccination (Sinopharm and Sinovac). J Stroke Cerebrovasc Dis. 2022;31(3):106298.
13. Hidayat R, Diafiri D, Zairinal RA, et al. Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series. Curr Neurovasc Res. 2021;18(3):360-363.
14. Sahin U, Muik A, Derhovanessian, E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature 2021, 586, 594–599, Erratum in: Nature 2021, 590, E17.
15. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature 2021, 600, 701–706.
16. Blauenfeldt RA, Kristensen SR, Ernstsen SL, et al. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J. Thromb. Haemostasis. 2021. 19 (7), 1771–1775
17. Malik, B., Kalantary, A, Rikabi, K, et al. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep. 2021. 14 (7), e243975
18. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination N Engl J Med, 384 (2021), 2092-101.
19. Noikongdee P, Police P, Phojanasenee T, et al.Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais Res Pract Thromb Haemost, 5. 2021, Article e12600
20. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland Nat Med.2021. 27; 1290-7.
21. S Pavord, M Scully, BJ Hunt, et al.Clinical features of vaccine-induced immune thrombocytopenia and thrombosis N Engl J Med, 2021.385; 1680-1689
22. Ren C, Yuan J, Tong S, et al. Memory Impairment Due to a Small Acute Infarction of the Columns of the Fornix. J Stroke Cerebrovasc Dis. 2018;27;7: e138-e143
23. Kim YS, Park HY, Yun KH, Park H, Cheong JS, Ha YS. Association of aortic knob calcification with intracranial stenosis in ischemic stroke patients. J Stroke. 2013;15(2):122-125
24. Hermann DM, Lehmann N, Gronewold J, et al. Thoracic aortic calcification is associated with incident stroke in the general population in addition to established risk factors. Eur Heart J Cardiovasc Imaging. 2015;16(6):684-690.
25. Park Y, Park HY, Yun KH, et al. The clinical significance of aortic calcification in chest radiography in community-dwelling, healthy adults: The PRESENT project. Neurology Asia 2019; 24(1): 1 – 7.
How to Cite
Mufida, K. (2023). DISORIENTATION AND MEMORY IMPAIRMENT AFTER COVID-19 VACCINATION (CORONAVAC): A CASE REPORT. Jurnal Kedokteran, 12(1), 1336-1339. https://doi.org/10.29303/jku.v12i1.863
Case Report